How DxPP™ Supports Oncology Drug Development
DxPP™ (Drug Prediction Platform) is First Ascent Biomedical’s research offering for pharmaceutical and biotech partners. It uses the same live-cell drug sensitivity testing and molecular profiling behind our clinical xDRIVE® platform to evaluate compounds and combinations in patient-derived tumor samples.
De-risk Phase I trials with human-relevant tumor models
- Strengthen regulatory submissions with functional drug response data that can support Investigational New Drug (IND) applications, FDA Breakthrough Therapy and Orphan Drug Designation requests, Pediatric Research Equity Act (PREA) compliance, and NIH Precision Medicine Initiative projects
- Discover novel drug combinations and pursue label expansion opportunities across new indications
- Uncover functional biomarkers tied to actual cancer behavior, no longer relying on predictive models
How It Works
We work with your team to generate patient-relevant data in 3 steps:
Scope the project and select target cancers and fresh patient samples, solid or hematologic.
Test your compounds and combinations ex vivo on live tumor cells.
Receive a prioritized report of drug response data in about 10 days from receipt of an acceptable samples.
Peer-Reviewed and Ready to Scale
Unlike genomics-only platforms or simulated AI models, First Ascent Biomedical data are grounded in real cancer cell response. Our approach has been published in peer-reviewed journals, including Nature Medicine (2024), and provides drug response data from live, patient-derived tumor cells to help partners prioritize compounds, combinations and patient populations.
- Faster, More Effective Development— Our platform tests drug response in patient-derived models to support more efficient early-stage research and stronger data for regulatory submissions.
- Reduced Clinical Trial Risk— Supports better patient targeting and trial design.
- Better-Informed Phase I Studies— Helps prioritize compounds for Phase I studies by testing them in human-relevant models, complementing in silico and animal testing.
- Unlock Portfolio Value— Identifies new combinations and indications to extend the value of existing assets, including those nearing loss of exclusivity.
- Hard Science, Real-World Validation— Backed by peer-reviewed research, including Nature Medicine(2024), and working with pharmaceutical and biotech partners around the world.
Let’s Accelerate Your Next Oncology Breakthrough
Join the Innovators Transforming Oncology
With DxPP™, pharma teams gain a new lens for discovery and validation, grounded in real-world patient biology.